Bristol Myers Squibb comes up short in bid to expand Opdualag in melanoma
Bristol Myers Squibb is striking out in its attempts to broaden the label of its first-in-class combo drug Opdualag. On Thursday, the company revealed that a phase 3 trial of Opdualag as an adjuvant treatment for patients with completely resected state III and stage IV melanoma did not achieve its primary endpoint.
Bristol Myers Squibb is striking out in its attempts to broaden the label of its first-in-class combo drug Opdualag. On Thursday, the company revealed that a phase 3 trial of Opdualag as an adjuvant treatment for patients with completely resected state III and stage IV melanoma did not achieve its primary endpoint.
